Fuda Cancer Hospital Reviews for International Patients
Fuda’s hospital status, campuses, and published treatment list can be checked on its own site.
This page does not quote independent patient, Reddit, or forum reviews.
Patient reviews do not establish treatment efficacy. A hospital claim stays hospital-published when a patient or an aggregator repeats it.
Offering a procedure does not establish a treatment outcome, and it does not show that the procedure fits one patient.
Want to check what these reviews can — and cannot — verify for your case?
Medical records → case screening → hospital route → next steps
Is Fuda Cancer Hospital Legitimate?
Searches framed as a Fuda scam question are a verification question, not a verdict. This page does not claim the hospital is or is not a scam. Check hospital status, affiliation, a written quote, and whether a story is hospital-published or independent.
Fuda’s current official English site describes the hospital as a tertiary tumor specialist hospital.
Current Fuda pages identify it as Fuda Cancer Hospital Affiliated to Jinan University.
Official contact information lists a North campus in Tianhe and a South campus in Haizhu.
Fuda says it has treated patients from more than 100 countries. This is a hospital-published figure, not an independent audit.
What this confirms: current Fuda pages document a tertiary cancer hospital affiliated with Jinan University, with two Guangzhou campuses. Whether a specific proposal fits a cancer type, stage, and treatment history is a separate question. It depends on the medical records.
Fuda Reputation: Which Credentials Are Current and Which Are Historical?
| Credential / reputation signal | What is supported | How to interpret it in 2026 |
|---|---|---|
| Tertiary cancer specialty hospital | Current Fuda hospital introduction. | Current official status |
| Affiliated with Jinan University | Current official English hospital naming and introduction. | Current official source |
| National Clinical Key Specialty history | Fuda reports participation in the national oncology specialty program and formal acceptance/evaluation in 2018. | Important historical credential |
| JCI accreditation | Fuda reports accreditation in 2014 and a reaccreditation survey in 2017. | Historical — not proof of current 2026 status |
| International patients | Fuda states it has treated patients from more than 100 countries. | Hospital-published experience claim |
Credential check: an old accreditation or historical award can still be context. It
is not a current 2026 badge unless the current accrediting body or registry confirms it.
What does the cited Baidu Health page say?
The cited third-party page is a 2026 Baidu Health evaluation of Guangzhou Fuda Cancer Hospital. It is platform material. It is not an official Fuda page, and it is not a set of patient reviews.
Minimally invasive treatment
The Baidu Health evaluation highlights minimally invasive treatment — particularly cryoablation and NanoKnife — as a feature it associates with Fuda. The same methods appear on Fuda’s own therapies page.
Not every cancer is described as suitable
The same evaluation says treatment choice depends on tumor type and stage, and it cautions that not every cancer is appropriate for a minimally invasive approach.
What this source is: Baidu Health identifies this content as AI-generated and expert-reviewed.
It is a secondary Chinese medical-platform summary. It is not an official Fuda statement, not a hospital ranking,
not a clinical guideline, and not independent patient-review evidence.
What kind of evidence this page uses
Current Fuda pages
Cited Fuda pages document tertiary status, affiliation with Jinan University, Tianhe and Haizhu campuses, a 2018 national oncology specialty record, historical JCI dates, the therapies directory, and a 14 August 2026 Yescarta page for selected adult large B-cell lymphoma.
Material the hospital issues
Fuda’s own site publishes treatment descriptions and patient stories. This page does not quote or link a specific patient story. A hospital-published story is selected by the hospital. It does not show that a method fits another person’s cancer.
Baidu Health summary
The cited Baidu Health page is a 2026 platform summary. The page describes itself as AI-generated and expert-reviewed. It discusses minimally invasive oncology and says not every cancer is suitable for that approach. It is not a set of patient reviews.
A category, with no citation on this page
Guidelines, trials, and peer-reviewed papers would sit here. This page does not cite one. A therapies list is not that evidence.
No independent review set is cited
This page does not contain quoted independent patient reviews, Reddit threads, or forum posts. No star rating or reputation score is given, because that material is not cited here.
How to read a hospital-published story
No specific Fuda patient story is linked or quoted on this page. If a story appears on the hospital’s own site, it shows what the hospital chose to publish. It does not show a typical result, a response rate, or that the same procedure fits another stage.
The journey the hospital describes
- Which diagnosis the hospital chose to describe
- Travel and inpatient coordination as described
- What follow-up the story mentions
An outcome for another patient
- How other patients at Fuda fare
- How many cases were not published
- Whether the described result is typical
- Whether the same procedure fits another stage
- A ranking against another hospital
If a story resembles a case: ask for the exact diagnosis, the indication, the treatment objective, and the evidence that applies to that disease. The story is not a prediction of the same result.
Treatments and capabilities published by Fuda
These points come from Fuda’s own pages. They describe what the hospital publishes. They do not show that a method fits an individual cancer.
Methods named on the current list
Fuda’s therapies page lists cryoablation, NanoKnife/IRE, vascular intervention, brachytherapy, microwave ablation, and CAR-T, among other techniques.
Yescarta pathway as published
Fuda’s CAR-T page describes a Yescarta / axicabtagene ciloleucel pathway for selected adult large B-cell lymphoma, including remote pre-treatment evaluation.
Patients from more than 100 countries
The current English introduction states that Fuda has treated patients from more than 100 countries. That figure is hospital-published. It is not an independent audit.
Two Guangzhou campuses
Official contact information lists a North campus in Tianhe and a South campus in Haizhu.
Fit for one diagnosis
A published method list does not show that cryoablation, NanoKnife, brachytherapy, or CAR-T fits a particular cancer, stage, or treatment history. That depends on the records.
Limitations and Questions That Deserve Extra Verification
Technology-led recommendations
When the treatment conversation begins with a device name — “NanoKnife,” “cryo,” “seed implantation” — ask the team to return to the disease question: why this technique is proposed for this diagnosis and stage, and what the alternative is.
Broad treatment indication lists
Hospital pages may list many cancers for one technique. That is not the same as guideline-level evidence for all of those cancers. The indication must be narrowed to the exact tumor, anatomy and stage.
Testimonials used as outcome evidence
A positive patient story cannot establish a survival figure, a response rate, or a ranking against another hospital. Ask what published evidence applies to the diagnosis instead.
Procedure fees and separate items
Fuda’s published billing page says major diagnosis and treatment project fees may refer to technology costs and may not include consumed medical materials or medication. Anesthesia and CT or ultrasound guidance can also be billed separately. The page is a 2014 publication of a 2011 letter, so a current written estimate still has to itemize what is included.
Fuda’s published capabilities and a separate hospital question
The columns describe what Fuda has published, and the separate question those pages do not answer. Neither column names a preferred hospital.
| Question | Published by Fuda | Separate access question |
|---|---|---|
| Listed methods | The therapies directory lists cryoablation, NanoKnife/IRE, vascular intervention, brachytherapy, microwave ablation, and CAR-T. | Whether the same records are being considered for surgery, radiation, or a systemic program at a large academic or public center. |
| Campuses and international statement | The contact page lists Tianhe and Haizhu. The introduction states that Fuda has treated patients from more than 100 countries. That figure is hospital-published. | How another center arranges international access is not described on this page. |
| CAR-T page | The 14 August 2026 page describes a Yescarta pathway for selected adult large B-cell lymphoma. | Whether the records ask about a different blood-cancer product or a transplant route. |
| Local methods | The published list includes local interventional methods. | Whether the records support a surgical, radiation, or systemic plan is not settled by that list. |
Sun Yat-sen University Cancer Center is a separate Guangzhou cancer hospital. This page does not compare outcome data and does not name a preferred hospital. The same diagnosis and records are what make a hospital-fit question concrete. Sun Yat-sen University Cancer Center.
What to Verify Before You Pay Fuda or Any Medical Facilitator
1. Doctor and department
Get the full doctor name, department and campus. Ask who will actually perform the procedure.
2. Exact diagnosis and stage
The proposal should match pathology, imaging, biomarkers and metastatic status.
3. Treatment goal
Curative, local control, bridge treatment, symptom relief or palliation should be stated explicitly.
4. Why this method?
Ask why Fuda proposes cryo, IRE, intervention, brachytherapy or CAR-T instead of the standard alternative.
5. Complete price
Request procedure, materials, medicines, anesthesia, imaging, room, nursing and likely exclusions.
6. Follow-up plan
Know what imaging is required, who reviews it and what happens if the cancer progresses after you return home.
Already have a Fuda quotation or treatment proposal?
The proposal, the pathology, and the scans are what a hospital-fit check uses. A review score is not part of that check.
What to Send for an Independent Fuda Case Review
Medical evidence
- Pathology report
- Immunohistochemistry
- Current stage
- CT / MRI / PET-CT reports
- DICOM imaging if available
- Relevant molecular / biomarker testing
- Prior surgery, radiation and systemic therapy
Fuda / facilitator material
- Treatment proposal
- Doctor or department name
- Quoted treatment method
- Number of expected procedures / cycles
- Cost estimate and deposit
- Included / excluded items
- Any outcome or testimonial claims used in the sales process
What the medical file is used for
The diagnosis and records
Pathology, stage, biomarkers, imaging, and previous treatment define the medical question.
The published hospital route
A Fuda proposal, when one exists, names a technique, a goal, and a department. Those details can be set next to the records and next to what Fuda has published.
Another center, when that question is open
The same file can be set next to another Chinese center’s published route. This page does not name a preferred hospital.
The written plan
A written estimate, campus, stay, and follow-up come after the treatment question is clear.
The records decide the next step
Pathology, scans, and any Fuda proposal are what a hospital-fit check uses. Hospital stories and platform summaries do not replace that file.
Related FUDA Due-Diligence Guides
Frequently Asked Questions
Direct answers to common trust, reputation and review questions about Guangzhou Fuda Cancer Hospital.
Is Fuda Cancer Hospital legitimate?
Yes. Guangzhou Fuda Cancer Hospital is an established tertiary cancer specialty hospital affiliated with Jinan University and operates two campuses in Guangzhou. The more important question is whether the exact treatment proposed by Fuda is appropriate for the patient’s cancer type, stage and prior treatment.
Does this page include independent Fuda patient reviews?
This page does not quote independent patient, Reddit, or forum reviews, and it does not give a star rating or a success rate. Fuda publishes patient stories on its own channels; none of those stories is linked here. The cited Baidu Health page is a platform summary that describes itself as AI-generated and expert-reviewed.
What does Baidu Health say about Fuda Cancer Hospital?
A 2026 Baidu Health evaluation identifies minimally invasive cancer treatment, particularly cryoablation and NanoKnife, as a distinguishing Fuda strength. It also cautions that treatment choice depends on cancer type and stage and that not every tumor is appropriate for a minimally invasive approach. Baidu Health marks the content as AI-generated and expert-reviewed, so it is a secondary source rather than a clinical guideline.
Is Fuda Cancer Hospital currently JCI accredited?
Fuda’s official materials report JCI accreditation in 2014 and a reaccreditation survey in 2017. Those historical records do not by themselves prove current JCI accreditation in 2026, so those pages are not presented here as a current 2026 credential. Current status needs a fresh registry confirmation.
Can Fuda patient stories prove that a treatment works?
No. A hospital-published patient story can illustrate one experience. It cannot establish a response rate, a survival figure, or a result that applies to another treatment. This page does not cite a guideline or a paper for that question. The patient’s own medical file is what a hospital-fit check uses.
Which treatments does Fuda’s therapies page list?
Fuda’s therapies directory lists cryoablation, NanoKnife/IRE, vascular intervention, brachytherapy, microwave ablation, and CAR-T, among other techniques. A 14 August 2026 Fuda page describes a Yescarta pathway for selected adult large B-cell lymphoma. That list does not show that any method fits an individual case.
How does Fuda compare with Sun Yat-sen University Cancer Center?
This page does not rank the hospitals. Fuda’s own pages list interventional methods, Tianhe and Haizhu contact details, and a 2026 Yescarta pathway for selected adult large B-cell lymphoma. Sun Yat-sen University Cancer Center is a separate Guangzhou cancer hospital. Suitability depends on the diagnosis and the medical records.
What should I verify before paying Fuda?
Confirm the doctor, department, correct campus, exact treatment method, treatment goal, evidence for the cancer type and stage, expected number of procedures, inpatient stay, major risks, follow-up and a written itemized estimate showing what is included and excluded.
Should a cancer hospital be chosen from online reviews?
This page does not contain an independent review set. Hospital-published stories and platform summaries do not show that a treatment fits a diagnosis. The medical records, the proposed method, and a written plan are what that question uses.
Can a Fuda proposal be set next to another Chinese hospital?
The same pathology, stage, scans, and previous treatment can be set next to another Chinese cancer center’s published route. This page does not rank hospitals by testimonials.
Sources and Evidence Labels
- Fuda current hospital introduction. Current official English pages describe Fuda as a tertiary tumor specialist hospital affiliated with Jinan University and state that the hospital has treated patients from more than 100 countries. Fuda official English site.
- Fuda current contact / campus information. Official contact materials list the North campus in Tianhe and South campus in Haizhu, Guangzhou. Fuda contact page.
- National Clinical Key Specialty history. Fuda’s Chinese official site reports formal acceptance/evaluation of its oncology specialty in 2018. Fuda official Chinese record.
- Historical JCI information. Fuda reports JCI accreditation in 2014 and a reaccreditation survey in 2017. Those pages are not proof of current 2026 accreditation status. Fuda JCI history.
- Fuda current Therapies directory. Confirms current treatment positioning around cryoablation, NanoKnife/IRE, vascular intervention, brachytherapy, microwave ablation, CAR-T and other techniques. Fuda therapies.
- Fuda CAR-T Therapy — August 14, 2026. Describes a Yescarta / axicabtagene ciloleucel pathway for selected adult large B-cell lymphoma and remote pre-treatment evaluation. Fuda CAR-T Therapy.
- Baidu Health evaluation — 广州复大肿瘤医院怎么样. Chinese patient-facing hospital evaluation emphasizing minimally invasive oncology, especially cryoablation and NanoKnife, while noting that not every cancer is suitable for minimally invasive treatment. The page identifies itself as AI-generated and expert-reviewed. It is a secondary platform summary, not an official Fuda statement and not independent patient-review evidence. Baidu Health evaluation.
- Fuda billing page — Billing and Other Financial Matters. Official hospital page. The underlying letter is dated 2011 and the page was published in 2014. It says major diagnosis and treatment project fees may refer to technology costs and may not include consumed medical materials or medication. Anesthesia and CT or ultrasound guidance can also be billed separately. It is not a current 2026 price list. Fuda official billing page.
Evidence labels: A, verified hospital facts, come from the cited Fuda pages. B, hospital-published material, includes stories the hospital may issue; none is quoted here. C, the cited Baidu Health page, is a platform summary. D, independent clinical evidence, is a category only: no guideline or paper is cited on this page. E, independent patient reviews, are not cited here.
Medical note: This page is for hospital due diligence and medical-travel research. It does not diagnose cancer, guarantee treatment availability, predict outcomes or provide an independent audited hospital ranking.
Verify the Treatment Proposal — Not Just the Hospital Name
Pathology, scans, and any Fuda or facilitator proposal show the method, the stated goal, and what still has to be confirmed before payment. This page does not rank Fuda against another hospital.
Check whether Fuda fits this case
Hospital facts and published material can be checked. They are not outcome evidence and do not show that Fuda fits one cancer. ParkMega can help organize records to screen whether an international-patient route is currently workable. This is not a booked commercial route, partnership claim, or acceptance guarantee.